(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Europe: 4 Urban communities for a Paramount Social Experience - 2Full SNAP benefits must be paid ‘promptly,’ USDA tells states as government reopens
- 3Viable Monetary Tips to Advance Your Monetary Circumstance
- 4The Excursion to Monetary Proficiency: Individual budget Triumphs
- 5Proficient Cultivating Devices for a Lovely and Useful Nursery in 2024
- 1st human missions to Mars should hunt for signs of life, report says
- Unusual 'ingredients' helped stars form in a galaxy near the Milky Way
- Investigating the Financial History of the World: A Succinct Outline
- Audits of the Top Science fiction Movies This Year
- Israel approves 19 new West Bank settlements in major annexation push
- Medtronic has 'significant firepower' for multiple acquisitions, executives say
- Israel’s mixed messaging on Christmas draws controversy
- 23 Most Amusing Messages At any point Sent Among Kids and Their Folks
- Was This Driver Simply Having A great time Or Behaving Like An Ass?
